Quantcast

Latest Quinazolines Stories

2009-06-29 07:00:00

Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli Lilly and Roche Will Drive Growth, According to a New Report from Decision Resources WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of targeted agents as well as increased use of existing agents in the maintenance setting...

2009-06-02 14:32:12

A U.S.-led international study suggests the combination of two drugs can delay disease progression for patients with advanced non-small cell lung cancer. Dr. Vincent Miller of the Memorial Sloan-Kettering Cancer Center, one of the study's leaders, said the goal was to determine whether adding erlotinib (Tarceva) to maintenance therapy with bevacizumab (Avastin), an agent commonly used as a component of treatment for advanced non-small cell lung cancer, would delay disease progression. This is...

e3ee029267b363ee362c969a267b606c1
2009-05-31 09:25:00

The mixture of two anti-cancer medications, along with chemotherapy, can gradually halt advanced non-small cell lung cancer, says a new study released on Saturday. Patients given Tarceva, made by the Swiss manufacturer Roche, and Avastin, saw their cancer growth halt more than a different group given just Avastin. 750 patients were randomly selected and given either Avastin and a placebo, or Avastin and Tarceva. The Tarceva group lived about 4.8 months before the cancer grew again,...

2009-05-28 07:00:00

WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28 /PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. The SEARCH (Sorafenib and...

2009-05-21 13:26:41

A class of drugs already approved as cancer treatments might also help to beat alcohol addiction. That's the conclusion of a discovery in flies of a gene, dubbed happyhour, that has an important and previously unknown role in controlling the insects' response to alcohol. Animals with a mutant version of the gene grow increasingly resistant to alcohol's sedative effects, the research shows. The researchers report further evidence that the gene normally does its work by blocking the so-called...

2009-05-19 07:00:00

SAN DIEGO, May 19 /PRNewswire/ -- Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene's president and CEO, will discuss the mechanism, antitumor properties and tumor selectivity of CX-4945, the Company's oral protein kinase inhibitor currently in Phase I clinical trials. This proprietary...

2009-05-14 17:17:00

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company...

2009-05-14 17:00:00

Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment BROOMFIELD, Colo., May 14 /PRNewswire/ -- Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a 314 patient...

2009-05-13 08:36:00

Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of...

2009-05-11 08:00:00

Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various presentations at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando beginning May 29. The presentations cover GSK Oncology research in solid and blood tumor treatment,...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related